Position in EVO
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$280
+$30 QoQ
Shares Held
100
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#28
of 34 holders
Holding Since
Sep 2023
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in EVO Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026JPMORGAN CHASE & CO holds $2,415,050,910 across 61 Drug Manufacturers - Specialty & Generic names. EVO ranks #58 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
6,398,674 | $1,078,432,506 | |
| 2 | TEVA |
Teva Pharmaceutical Industries Ltd
|
6,981,234 | $236,524,202 | |
| 3 | ZTS |
Zoetis Inc.
|
2,624,825 | $188,619,917 | |
| 4 | HIMS |
Hims & Hers Health, Inc.
|
4,766,781 | $165,264,292 | |
| 5 | UTHR |
UNITED THERAPEUTICS Corp
|
275,358 | $149,197,220 | |
| 6 | VTRS |
Viatris Inc
|
7,322,267 | $116,277,595 | |
| 7 | HLN |
Haleon plc
|
10,824,395 | $100,991,599 | |
| 8 | LNTH |
Lantheus Holdings, Inc.
|
699,229 | $77,572,458 |
All Filings in EVO
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $280 | 100 | Shares | Defined | 2026-08-12 | |
| 2026-03-31 | $250 | 100 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $308 | 100 | Shares | Defined | 2026-02-11 | |
| 2023-12-31 | $1,583 | 135 | Shares | Sole | 2024-12-26 | |
| 2023-09-30 | $1,332 | 135 | Shares | Sole | 2023-11-14 | |
| No filing history on record for this holder in this stock. | ||||||